George Kemble Biography and Net Worth

Chairman of Sagimet Biosciences

Dr. Kemble joined Sagimet Biosciences in August 2011 as its chief scientific officer and served as chief executive officer from October 2015 until October 2022, when he transitioned to the role of executive chairman. In May 2025, Dr. Kemble moved into the role of non-executive Chair of the Board. As CSO, Dr. Kemble directed Sagimet’s medicinal chemistry, research, translational and CMC groups, and worked on several programs including the lead product candidate, denifanstat. Prior to joining the company, Dr. Kemble served as the senior vice president of R&D and head of research at MedImmune, Inc., a subsidiary of Astra-Zeneca PLC. During his tenure, he was responsible for a large group of scientists dedicated to the research and development of programs across a number of therapeutic areas, including the launch of FluMist®, the first innovation in influenza vaccines in over 60 years. Dr. Kemble received a BS from the University of Santa Clara,a PhD from Stanford University and completed post-doctoral training at UCSF, where he worked on a number of different human viruses.

What is George Kemble's net worth?: The estimated net worth of George Kemble is at least $514.38 thousand as of November 20th, 2025. Dr. Kemble owns 81,005 shares of Sagimet Biosciences stock worth more than $514,382 as of December 5th. This net worth evaluation does not reflect any other assets that Dr. Kemble may own. Additionally, Dr. Kemble receives a salary of $484,000.00 as Chairman at Sagimet Biosciences. Learn More about George Kemble's net worth.
How old is George Kemble?: Dr. Kemble is currently 62 years old. There are 3 older executives and no younger executives at Sagimet Biosciences. Learn More on George Kemble's age.
What is George Kemble's salary?: As the Chairman of Sagimet Biosciences Inc., Dr. Kemble earns $484,000.00 per year. There are 2 executives that earn more than Dr. Kemble. The highest earning executive at Sagimet Biosciences is Mr. David A. Happel, CEO, President & Director, who commands a salary of $836,180.00 per year. Learn More on George Kemble's salary.
How do I contact George Kemble?: The corporate mailing address for Dr. Kemble and other Sagimet Biosciences executives is , , . Sagimet Biosciences can also be reached via phone at 650-561-8600 and via email at [email protected]. Learn More on George Kemble's contact information.
Has George Kemble been buying or selling shares of Sagimet Biosciences?: During the last quarter, George Kemble has sold $289,820.72 in shares of Sagimet Biosciences stock. Most recently, George Kemble sold 37,688 shares of the business's stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $7.69, for a transaction totalling $289,820.72. Following the completion of the sale, the chairman now directly owns 81,005 shares of the company's stock, valued at $622,928.45. Learn More on George Kemble's trading history.
Who are Sagimet Biosciences' active insiders?: Sagimet Biosciences' insider roster includes David Happel (Chief Executive Officer & Director), George Kemble (Chairman), Eduardo Martins (Chief Medical Officer), Elizabeth Rozek (General Counsel), and Beth Seidenberg (Director). Learn More on Sagimet Biosciences' active insiders.
Are insiders buying or selling shares of Sagimet Biosciences?: During the last twelve months, insiders at the sold shares 4 times. They sold a total of 122,223 shares worth more than $1,061,625.27. The most recent insider tranaction occured on November, 20th when Chairman George Kemble sold 37,688 shares worth more than $289,820.72. Insiders at Sagimet Biosciences own 14.7% of the company. Learn More about insider trades at Sagimet Biosciences.
Information on this page was last updated on 11/20/2025.

George Kemble Insider Trading History at Sagimet Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/20/2025	Sell	37,688	$7.69	$289,820.72	81,005
7/23/2024	Sell	23,625	$3.17	$74,891.25	118,693
7/19/2024	Sell	14,062	$3.10	$43,592.20	142,318

George Kemble Buying and Selling Activity at Sagimet Biosciences

Sagimet Biosciences Company Overview

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Today's Range

Now: $6.35

$6.19

$6.55

50 Day Range

MA: $7.56

$6.09

$9.14

2 Week Range

Now: $6.35

$1.73

$11.41

Volume

809,338 shs

Average Volume

478,418 shs

Market Capitalization

$206.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.32

George Kemble Biography and Net Worth

What is George Kemble's net worth?

How old is George Kemble?

What is George Kemble's salary?

How do I contact George Kemble?

Has George Kemble been buying or selling shares of Sagimet Biosciences?

Who are Sagimet Biosciences' active insiders?

Are insiders buying or selling shares of Sagimet Biosciences?